Iguratimod API

Iguratimod API

​Chinese product name: Ellamod
Chinese alias: N-[3-(carboxamido)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]methanesulfonamide
English product name: Iguratimod
Cas#123663-49-0
Molecular formula: C17H14N2O6S
Molecular weight: 374.3679
Appearance and properties: white powder
Domestic registration number of API: Y20190021542
Iguratimod API is for anti-rheumatic drug, synovitis drug.

Send Inquiry

Product Description

Formula

Chinese product name: Ellamod

Chinese alias: N-[3-(carboxamido)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]methanesulfonamide

English product name: Iguratimod

Cas#123663-49-0

Molecular formula: C17H14N2O6S

Molecular weight: 374.3679

Appearance and properties: white powder

Domestic registration number of API: Y20190021542

Iguratimod API is for anti-rheumatic drug, synovitis drug.



Iguratimod API (active pharmaceutical ingredient) is a novel small-molecule immunomodulatory agent that has garnered significant attention in the treatment of autoimmune disorders, particularly rheumatoid arthritis (RA). Developed as a disease-modifying antirheumatic drug (DMARD), Iguratimod API exhibits unique mechanisms of action, distinguishing it from conventional therapies. This article explores the applications, strengths, and challenges associated with Iguratimod API, emphasizing its growing role in modern pharmacotherapy.

Therapeutic Applications of Iguratimod API

Rheumatoid Arthritis (RA): Iguratimod API is primarily indicated for RA management. It inhibits pro-inflammatory cytokines, including TNF-α and IL-6, while suppressing Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathways. Clinical trials demonstrate its efficacy in reducing joint inflammation and slowing disease progression.

Other Autoimmune Disorders: Emerging studies suggest potential applications of Iguratimod API in systemic lupus erythematosus (SLE) and osteoarthritis, owing to its anti-fibrotic and cartilage-protective properties.

Combination Therapy: Iguratimod API is increasingly used alongside methotrexate or biologics, enhancing therapeutic outcomes in refractory RA cases.

Advantages of Iguratimod API

Dual Mechanism of Action: Unlike traditional DMARDs, Iguratimod API combines immunomodulation with direct inhibition of osteoclastogenesis, addressing both inflammation and bone erosion.

Improved Safety Profile: Compared to corticosteroids or non-steroidal anti-inflammatory drugs (NSAIDs), Iguratimod API exhibits fewer gastrointestinal and cardiovascular side effects.

Oral Administration: As an orally bioavailable API, Iguratimod offers convenience over injectable biologics, improving patient compliance.

Cost-Effectiveness: Iguratimod API is more affordable than biologic agents, making it accessible in resource-limited settings.

Limitations and Challenges

Delayed Onset of Action: The therapeutic effects of Iguratimod API may take 4–8 weeks to manifest, limiting its utility in acute flare-ups.

Hepatotoxicity Risks: Elevated liver enzymes have been reported in some patients, necessitating regular monitoring.

Limited Global Approval: While Iguratimod API is approved in Japan and China, its adoption remains restricted in Western markets due to insufficient long-term safety data.

Drug Interactions: Co-administration with strong CYP3A4 inducers or inhibitors may alter Iguratimod API’s pharmacokinetics, requiring dose adjustments.

Future Perspectives

Ongoing research aims to expand the applications of Iguratimod API, including its potential in COVID-19-related cytokine storms and neurodegenerative diseases. Furthermore, formulation innovations, such as nanoparticle-based delivery systems, could enhance its bioavailability and targeting efficiency.

Conclusion

Iguratimod API represents a promising therapeutic agent with multifaceted applications in autoimmune diseases. Its unique mechanisms, oral bioavailability, and cost-effectiveness position it as a valuable alternative to conventional therapies. However, challenges such as delayed efficacy and hepatotoxicity underscore the need for vigilant patient management. As clinical evidence grows, Iguratimod API may solidify its role in global rheumatology practice, provided its safety and versatility are further validated.





Hot Tags: Iguratimod API, China, Manufacturer, Supplier, Factory, High Quality
Related Category
Send Inquiry
Please feel free to give your inquiry in the form below. We will reply you in 24 hours.
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept